3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study
NCT00275444
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
216
Enrollment
INDUSTRY
Sponsor class
Conditions
HIV Infections
Interventions
DRUG:
Tipranavir
Sponsor
Boehringer Ingelheim